ES2629739T3 - Composición farmacéutica estable para el tratamiento de osteoporosis - Google Patents

Composición farmacéutica estable para el tratamiento de osteoporosis Download PDF

Info

Publication number
ES2629739T3
ES2629739T3 ES13859631.7T ES13859631T ES2629739T3 ES 2629739 T3 ES2629739 T3 ES 2629739T3 ES 13859631 T ES13859631 T ES 13859631T ES 2629739 T3 ES2629739 T3 ES 2629739T3
Authority
ES
Spain
Prior art keywords
composition
risedronate
vitamin
granules
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13859631.7T
Other languages
English (en)
Spanish (es)
Inventor
María Lourdes GARCÍA MONDRAGÓN
Alejandro REYES SANTIAGO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Landsteiner Scient SA de CV
LANDSTEINER SCIENTIFIC de C V SA
Original Assignee
Landsteiner Scient SA de CV
LANDSTEINER SCIENTIFIC de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landsteiner Scient SA de CV, LANDSTEINER SCIENTIFIC de C V SA filed Critical Landsteiner Scient SA de CV
Application granted granted Critical
Publication of ES2629739T3 publication Critical patent/ES2629739T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13859631.7T 2012-12-03 2013-10-30 Composición farmacéutica estable para el tratamiento de osteoporosis Active ES2629739T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MX2012014071A MX350569B (es) 2012-12-03 2012-12-03 Composicion farmaceutica estable para el tratamiento de osteoporosis.
MX2012014071 2012-12-03
PCT/MX2013/000130 WO2014088385A1 (es) 2012-12-03 2013-10-30 Composición farmacéutica estable para el tratamiento de osteoporosis

Publications (1)

Publication Number Publication Date
ES2629739T3 true ES2629739T3 (es) 2017-08-14

Family

ID=50883732

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13859631.7T Active ES2629739T3 (es) 2012-12-03 2013-10-30 Composición farmacéutica estable para el tratamiento de osteoporosis

Country Status (6)

Country Link
US (1) US20150342968A1 (enExample)
EP (1) EP2926817B1 (enExample)
JP (1) JP6374879B2 (enExample)
ES (1) ES2629739T3 (enExample)
MX (1) MX350569B (enExample)
WO (1) WO2014088385A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
EP4210757A4 (en) * 2020-09-11 2024-10-23 Comera Life Sciences, Inc. EXCELLENT COMPOUNDS FOR PROTEIN FORMULATIONS
CN119385959B (zh) * 2025-01-03 2025-04-01 山东第一医科大学附属省立医院(山东省立医院) 一种利塞膦酸钠片剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004807A (es) 2004-05-19 2005-11-24 Merck & Co Inc Composiciones y metodos para inhibir la resorcion osea.
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
KR100822133B1 (ko) 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
JP2010513475A (ja) * 2006-12-20 2010-04-30 ランドシュタイナー サイエンティフィック エッセ アー デ シー ヴイ リセドロネートおよびビタミンｄ組成物
KR100844256B1 (ko) * 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
EP2201937A1 (en) * 2008-12-23 2010-06-30 Teva Pharmaceutical Industries Ltd. Formulations comprising vitamin D or derivatives thereof
TR200900878A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
KR101102364B1 (ko) * 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
KR20120005228A (ko) * 2010-07-08 2012-01-16 주식회사 네비팜 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법

Also Published As

Publication number Publication date
EP2926817A4 (en) 2016-05-18
US20150342968A1 (en) 2015-12-03
EP2926817B1 (en) 2017-03-29
MX350569B (es) 2017-09-11
EP2926817A1 (en) 2015-10-07
JP2016501226A (ja) 2016-01-18
WO2014088385A1 (es) 2014-06-12
JP6374879B2 (ja) 2018-08-15
MX2012014071A (es) 2014-06-23

Similar Documents

Publication Publication Date Title
ES2921141T3 (es) Forma farmacéutica oral sólida entérica de un bisfosfonato que contiene un agente quelante
ES2908655T3 (es) Composiciones farmacéuticas sólidas y procedimientos para su producción
RU2381791C2 (ru) Лекарственные формы ризедроната
KR101535310B1 (ko) 비타민 및 미네랄 보충제의 개선된 안정성
US20050089573A1 (en) Oral pharmaceutical formulation containing ibandronate
CN112770726A (zh) 大麻素的缓释配方
KR101102364B1 (ko) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
JP2010518822A5 (enExample)
ES2705074T3 (es) Composición sólida para administración oral que contiene ácido ibandrónico o una sal farmacéuticamente aceptable del mismo y vitamina D
US20090317460A1 (en) Solid dosage form
AU2017394478B2 (en) Medical treatment comprising enteral administration of edaravone
EP2926817B1 (en) Stable pharmaceutical composition for treating osteoporosis
ES2749752T3 (es) Composiciones administrables por vía oral que comprenden calcio
AU2014239651A1 (en) Method of treating vitamin B12 deficiency
US20160022594A1 (en) Soft gel encapsulation
JP7640453B2 (ja) 医薬製剤およびその製造方法
ES2733113T3 (es) Composición farmacéutica estable de una sal de vinorelbina soluble en agua
WO2011113965A1 (es) Composición farmacéutica en forma sólida que contiene isoflavonas, una sal de calcio y vitamina d3
EP2661262B1 (en) Improved bisphosphonate formulations
KR20120105738A (ko) 장용코팅된 경구용 제제
US20230165928A1 (en) Compositions and methods comprising stable reduced glutathione
US20130022645A1 (en) Pharmaceutical formulations of bisphosphonate with enhanced oral bioavailability
CA3050031C (en) Medical treatment comprising enteral administration of edaravone
ES2731598T3 (es) Formulación pediátrica que comprende ácido biliar
KR20110088474A (ko) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물